Test Price
650 AED✅ Home Collection Available
t(9;11) MLL-AF9 Fusion PCR Qualitative Test in UAE | 650 AED | DHA Licensed
Executive Summary & Core Metrics
This DHA-licensed molecular assay offers qualitative detection of the MLL-AF9 fusion transcript arising from t(9;11)(p21-22;q23), using real-time PCR (qPCR) under ISO 9001:2015-accredited processes. The test is pivotal for diagnosis, risk stratification, and minimal residual disease monitoring in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
- Accuracy Guarantee: 99.9% diagnostic sensitivity via real-time PCR.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complimentary telephonic post-test interpretation with a DHA-licensed Consultant Medical Geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The t(9;11) MLL-AF9 fusion qualitative PCR test detects the hallmark chromosomal translocation in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), guiding risk stratification and targeted therapy selection. This assay employs real-time PCR with single-molecule sensitivity, enabling detection of the MLL-AF9 fusion transcript at levels as low as 0.01% blasts.
| Feature | Our Test (MLL-AF9 qPCR) | Closest Alternative (FISH) |
|---|---|---|
| Precision | Single-molecule sensitivity; quantitative if needed | Cytogenetic, lower sensitivity (~5%) |
| Methodology | Real-Time PCR (qPCR) – ISO 9001:2015 | Fluorescence In-Situ Hybridisation |
| Turnaround Time | 3–4 business days | 5–7 working days |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I emphasize that this MLL-AF9 PCR test is a critical tool for diagnosing and monitoring MLL-rearranged leukemias. However, it must be interpreted in conjunction with bone marrow morphology, cytogenetics, and clinical findings. Never modify treatment based solely on this test without consulting your hematologist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory & Medication Warning
⚠ Critical Advisory
Do not discontinue or modify any prescribed chemotherapy, immunosuppressant, or supportive therapy without direct consultation with your treating oncologist. Abrupt changes can provoke life‑threatening complications. Always present this molecular result alongside complete blood counts and clinical status.
Exclusion Criteria & Emergency Red Flags
🚨 Safety Exclusion Criteria & ER Red Flags
- Exclusion: Active, uncontrolled sepsis or haemodynamic instability; absolute contraindication to bone marrow aspiration; severe thrombocytopenia (<20,000/µL) without platelet cover; inability to provide informed consent.
- ER Red Flags (post‑collection): Uncontrolled bleeding at puncture site, sudden onset of severe bone pain, fever >38.5°C, or signs of acute tumour lysis (muscle cramps, cardiac arrhythmia, oliguria). Seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. How accurate is this MLL-AF9 PCR test for diagnosing AML?
This test delivers 99.9% diagnostic sensitivity using real-time PCR, making it the gold‑standard molecular tool for detecting the MLL-AF9 fusion transcript. However, a negative result does not rule out other AML subtypes, and results must always be correlated with bone marrow morphology and cytogenetics to ensure a complete diagnosis.
2. How long does it take to get results, and do I need to fast?
Results are typically ready in 3–4 business days from sample receipt. No fasting or special preparation is required. The sample is bone marrow aspirate collected under sterile conditions in an accredited hospital. Please provide your full clinical history and avoid anticoagulants if possible; the specimen is collected in an EDTA tube and transported at controlled temperature.
3. Can this test be used to monitor treatment response over time?
Absolutely—serial MLL-AF9 qPCR testing is a validated method for minimal residual disease (MRD) monitoring in MLL‑rearranged leukemias and can detect molecular relapse months before clinical signs appear. Always compare sequential results under the same laboratory conditions, and never alter therapy based on a single value without clinical correlation. Your hematologist will determine the optimal monitoring schedule.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
DNA Labs UAE operates under DHA Facility License No. 1143 and strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All genomic data is encrypted, access-controlled, and never shared without explicit patient consent.
Clinical & Logistical Metadata
| Test Name | t(9;11) MLL-AF9 Fusion PCR, Qualitative |
| Price (AED) | 650 |
| Turnaround Time | 3–4 business days |
| Sample Type / Matrix | Bone marrow aspirate (hospital extraction only; mobile phlebotomy disabled) |
| Methodology Used | Real-Time PCR (qPCR) – ISO 9001:2015 |
| ICD-10-CM Code | C92.0 (Acute myeloid leukemia) – translocation t(9;11)(p21;q23) may be specified |
| LOINC Code | 60595-2 (MLL-AF9 fusion transcript (t(9;11)) [Presence] in Blood or Tissue by RT-PCR) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians